These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 26369501

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR, Sabatine MS.
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [Abstract] [Full Text] [Related]

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P, Just IA, Kaschina E.
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA, Lyon RA, Ling H.
    Vasc Health Risk Manag; 2016 Jun; 12():163-9. PubMed ID: 27143910
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L, Peng H, Xu D, Zhao S.
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [Abstract] [Full Text] [Related]

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
    Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U.
    BMC Cardiovasc Disord; 2014 Sep 20; 14():121. PubMed ID: 25240705
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2344-53. PubMed ID: 22463922
    [Abstract] [Full Text] [Related]

  • 15. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP, Paolillo S, Trimarco B.
    G Ital Cardiol (Rome); 2015 Jan 19; 16(1):44-51. PubMed ID: 25689751
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E, Salvetti M.
    High Blood Press Cardiovasc Prev; 2016 Sep 19; 23(3):217-30. PubMed ID: 27567901
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.
    Lepor NE, Contreras L, Desai C, Kereiakes DJ.
    Rev Cardiovasc Med; 2014 Sep 19; 15(4):290-307; quiz 308-9. PubMed ID: 25662924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.